Seeking Alpha

Eli Lilly's (LLY) Effient blood thinner surprisingly failed to perform better than Plavix, an...

Eli Lilly's (LLY) Effient blood thinner surprisingly failed to perform better than Plavix, an older drug, in study of 9,000 patients. While the outcome is a blow for the hopes of Eli Lilly and partner Daiichi Sankyo in expanding the use of Effient, it's good news for AztraZenica (AZN), whose Brilinta does have an edge over Plavix. The results were reported at the annual congress of the European Society of Cardiology.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs